ATE537150T1 - Zur behandlung gynäkologischer erkrankungen geeignete pyrazolderivate - Google Patents

Zur behandlung gynäkologischer erkrankungen geeignete pyrazolderivate

Info

Publication number
ATE537150T1
ATE537150T1 AT06809167T AT06809167T ATE537150T1 AT E537150 T1 ATE537150 T1 AT E537150T1 AT 06809167 T AT06809167 T AT 06809167T AT 06809167 T AT06809167 T AT 06809167T AT E537150 T1 ATE537150 T1 AT E537150T1
Authority
AT
Austria
Prior art keywords
treatment
pyrazole derivatives
gynecological diseases
derivatives suitable
gynecological
Prior art date
Application number
AT06809167T
Other languages
English (en)
Inventor
Paul Bradley
Kevin DACK
Patrick Johnson
Sarah Skerratt
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Application granted granted Critical
Publication of ATE537150T1 publication Critical patent/ATE537150T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT06809167T 2005-11-08 2006-10-26 Zur behandlung gynäkologischer erkrankungen geeignete pyrazolderivate ATE537150T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73509105P 2005-11-08 2005-11-08
PCT/IB2006/003080 WO2007054770A2 (en) 2005-11-08 2006-10-26 Pyrazole derivatives and their medical use

Publications (1)

Publication Number Publication Date
ATE537150T1 true ATE537150T1 (de) 2011-12-15

Family

ID=37909834

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06809167T ATE537150T1 (de) 2005-11-08 2006-10-26 Zur behandlung gynäkologischer erkrankungen geeignete pyrazolderivate

Country Status (35)

Country Link
US (2) US7309712B2 (de)
EP (1) EP1948615B1 (de)
JP (1) JP4234786B1 (de)
KR (1) KR100997595B1 (de)
CN (1) CN101304974A (de)
AP (1) AP2008004463A0 (de)
AR (1) AR056780A1 (de)
AT (1) ATE537150T1 (de)
AU (1) AU2006313478A1 (de)
BR (1) BRPI0618630A2 (de)
CA (1) CA2628844C (de)
CR (1) CR9959A (de)
CY (1) CY1112286T1 (de)
DK (1) DK1948615T3 (de)
DO (1) DOP2006000245A (de)
EA (1) EA014693B1 (de)
EC (1) ECSP088431A (de)
ES (1) ES2376252T3 (de)
GT (1) GT200600478A (de)
HN (1) HN2006037713A (de)
IL (1) IL190806A0 (de)
MA (1) MA29940B1 (de)
NL (1) NL2000299C2 (de)
NO (1) NO20082504L (de)
PE (1) PE20070642A1 (de)
PL (1) PL1948615T3 (de)
PT (1) PT1948615E (de)
RS (1) RS20080191A (de)
SI (1) SI1948615T1 (de)
TN (1) TNSN08202A1 (de)
TW (1) TWI321563B (de)
UA (1) UA90763C2 (de)
UY (1) UY29904A1 (de)
WO (1) WO2007054770A2 (de)
ZA (1) ZA200803670B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0934061B3 (de) 1996-07-24 2015-01-21 Warner-Lambert Company LLC Isobutylgaba und dessen derivate zur schmerzbehandlung
PL1948615T3 (pl) * 2005-11-08 2012-04-30 Pfizer Ltd Pochodne pirazolu przydatne w leczeniu chorób ginekologicznych
WO2008014199A2 (en) 2006-07-28 2008-01-31 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the cb2 receptor
KR20090069318A (ko) 2006-09-25 2009-06-30 베링거 인겔하임 인터내셔날 게엠베하 Ｃｂ2 수용체를 조절하는 화합물
WO2008135824A1 (en) * 2007-05-02 2008-11-13 Pfizer Limited Oxyalkylpyrazole compounds useful in therapy
EP2217565B1 (de) 2007-11-07 2013-05-22 Boehringer Ingelheim International GmbH Cb2 rezeptor-modulierende verbindungen
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
US20120015988A1 (en) * 2008-05-13 2012-01-19 Boehringer Ingelheim International Gmbh Sulfone Compounds Which Modulate The CB2 Receptor
EP2326629B1 (de) 2008-07-10 2013-10-02 Boehringer Ingelheim International GmbH Den cb2-rezeptor modulierende sulfonverbindungen
CA2737645A1 (en) 2008-09-25 2010-04-01 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the cb2 receptor
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
WO2010147791A1 (en) 2009-06-16 2010-12-23 Boehringer Ingelheim International Gmbh Azetidine 2 -carboxamide derivatives which modulate the cb2 receptor
EP2480544A1 (de) 2009-09-22 2012-08-01 Boehringer Ingelheim International GmbH Verbindungen für selektive cb2-rezeptormodulation
US20110136815A1 (en) * 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
EP2523936A1 (de) 2010-01-15 2012-11-21 Boehringer Ingelheim International GmbH Cb2 rezeptor-modulierende verbindungen
US8329735B2 (en) 2010-03-05 2012-12-11 Boehringer Ingelheim International Gmbh Tetrazole compounds which selectively modulate the CB2 receptor
US20110263606A1 (en) * 2010-04-26 2011-10-27 Horst Zerbe Solid oral dosage forms comprising tadalafil
WO2012012307A1 (en) 2010-07-22 2012-01-26 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the cb2 rece
EP2803668A1 (de) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Neuartige (Cyano-dimethyl-methyl)-isoxazole und -[1,3,4]-thiadiazole
TWI886480B (zh) * 2017-04-06 2025-06-11 美商富曼西公司 殺真菌之噁二唑
AU2019362242A1 (en) * 2018-10-18 2021-05-27 Nanjing Sanhome Pharmaceutical Co., Ltd. Compound as TGF-β R1 inhibitor and application thereof
RU2711615C1 (ru) * 2019-09-12 2020-01-17 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта" Способ лечения эндометриоза на основании экспериментальной модели у крыс
CN111269097B (zh) * 2020-04-02 2023-02-17 苏州爱玛特生物科技有限公司 一种多元环双取代的1,3-丙二酮类化合物的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6281638A (ja) * 1985-10-07 1987-04-15 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料
JPS63313784A (ja) * 1987-03-12 1988-12-21 Zeria Shinyaku Kogyo Kk 新規ピラゾール誘導体およびその製造法ならびにこれを有効成分とする抗潰瘍剤
DE4414792A1 (de) * 1993-08-11 1995-02-16 Bayer Ag Arzneimittel enthaltend 1-Thiocarbamoyl-5-hydroxypyrazolen und deren Verwendung als Mittel zur Bekämpfung des septischen Schocks
SI1762567T1 (sl) * 2001-04-10 2012-08-31 Pfizer Derivati pirazola za zdravljenje HIV-a
GB0229618D0 (en) * 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
PL1948615T3 (pl) * 2005-11-08 2012-04-30 Pfizer Ltd Pochodne pirazolu przydatne w leczeniu chorób ginekologicznych

Also Published As

Publication number Publication date
MA29940B1 (fr) 2008-11-03
ZA200803670B (en) 2009-03-25
HN2006037713A (es) 2010-06-09
WO2007054770A3 (en) 2007-10-04
US20080085919A1 (en) 2008-04-10
NL2000299A1 (nl) 2007-05-09
DK1948615T3 (da) 2012-02-06
UA90763C2 (ru) 2010-05-25
SI1948615T1 (sl) 2012-02-29
AR056780A1 (es) 2007-10-24
TWI321563B (en) 2010-03-11
GT200600478A (es) 2007-06-08
PT1948615E (pt) 2012-02-03
AP2008004463A0 (en) 2008-06-30
ES2376252T3 (es) 2012-03-12
JP2009514938A (ja) 2009-04-09
DOP2006000245A (es) 2007-06-30
KR100997595B1 (ko) 2010-11-30
NL2000299C2 (nl) 2007-11-20
CA2628844C (en) 2011-12-06
CN101304974A (zh) 2008-11-12
ECSP088431A (es) 2008-06-30
PL1948615T3 (pl) 2012-04-30
WO2007054770A2 (en) 2007-05-18
RS20080191A (sr) 2009-07-15
US7309712B2 (en) 2007-12-18
US20070105909A1 (en) 2007-05-10
KR20080056761A (ko) 2008-06-23
EP1948615B1 (de) 2011-12-14
JP4234786B1 (ja) 2009-03-04
TW200804295A (en) 2008-01-16
AU2006313478A1 (en) 2007-05-18
CR9959A (es) 2008-08-01
NO20082504L (no) 2008-06-05
EP1948615A2 (de) 2008-07-30
US7425569B2 (en) 2008-09-16
BRPI0618630A2 (pt) 2011-09-06
EA200801053A1 (ru) 2008-10-30
IL190806A0 (en) 2008-11-03
UY29904A1 (es) 2007-06-29
TNSN08202A1 (fr) 2009-10-30
CA2628844A1 (en) 2007-05-18
CY1112286T1 (el) 2015-12-09
EA014693B1 (ru) 2010-12-30
PE20070642A1 (es) 2007-08-24

Similar Documents

Publication Publication Date Title
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
ATE534633T1 (de) Indazolderivate zur behandlung von hsp90- induzierten krankheiten
ATE549330T1 (de) Zur behandlung von erkrankungen des zns geeignete derivate des 4-piperazin-1-yl-4-benzoäbüthiophens
DE602007004092D1 (de) C-met-proteinkinasehemmer zur behandlung proliferativer erkrankungen
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
DK1948615T3 (da) Til behandling af gynækologiske sygdomme egnede pyrazolderivater
EP1981526A4 (de) Adiponectin zur behandlung verschiedener erkrankungen
ATE440866T1 (de) Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
DE602006019838D1 (de) Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
ATE542823T1 (de) 4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen
ATE476414T1 (de) Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE517085T1 (de) Zur behandlung von atemwegserkrankungen geeignete phenoxyessigsäurederivate
EP2135858A4 (de) Zusammensetzung zur behandlung von infektionserkrankungen
EP3769718C0 (de) Vorrichtung zur behandlung von darmerkrankungen
ATE429218T1 (de) Pinolensäure zur behandlung von übergewicht
FI20095600L (fi) Koostumus ihosairauksien hoitoa varten
ATE484279T1 (de) Isosorbid-mononitrat-derivate zur behandlung von darmerkrankungen
EP1965827A4 (de) Behandlung von entmyelinisierenden erkrankungen
ATE525355T1 (de) 1-ä(4-äbenzoyl(methyl)aminoü-3- (phenyl)butylüazetidinderivate zur behandlung von gastrointestinalen erkrankungen 1
EP1773779A4 (de) Nicotinrezeptoragonisten zur behandlung entzündlicher krankheiten
ATE439843T1 (de) S-mirtazapin zur behandlung von hitzewallungen